Patent Restoration/ANDA Compromise
House Health Subcmte. Chairman Waxman (D-Calif.) will have a chance to explain the rough outlines of the compromise bill being worked on by his staff when he addresses the First Annual Generic Drug Conference in NYC April 6. Delay in release of the draft bill has been due to difficulty in developing language for the patent restoration part of the two-tier legislation.
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.